Galmed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:GLMD)

$5.57 +0.17 (+3.15 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$5.57
Today's Range$5.30 - $5.74
52-Week Range$3.61 - $12.22
Volume53,245 shs
Average Volume142,741 shs
Market Capitalization$70.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42

About Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals logoGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Debt-to-Equity RatioN/A
Current Ratio3.05%
Quick Ratio3.05%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$470,000.00
Price / Sales150.86
Cash FlowN/A
Price / CashN/A
Book Value$0.91 per share
Price / Book6.12

Profitability

Trailing EPS($1.11)
Net Income$-16,950,000.00
Net Margins-1,242.49%
Return on Equity-167.83%
Return on Assets-110.52%

Miscellaneous

Employees16
Outstanding Shares12,730,000

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) released its quarterly earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.04. Galmed Pharmaceuticals had a negative net margin of 1,242.49% and a negative return on equity of 167.83%. View Galmed Pharmaceuticals' Earnings History.

When will Galmed Pharmaceuticals make its next earnings announcement?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 22nd 2018. View Earnings Estimates for Galmed Pharmaceuticals.

Where is Galmed Pharmaceuticals' stock going? Where will Galmed Pharmaceuticals' stock price be in 2018?

4 analysts have issued 12-month target prices for Galmed Pharmaceuticals' shares. Their predictions range from $14.00 to $32.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $22.25 in the next twelve months. View Analyst Ratings for Galmed Pharmaceuticals.

What are Wall Street analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (1/11/2018)
  • 2. Maxim Group analysts commented, "Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies." (11/9/2017)

Who are some of Galmed Pharmaceuticals' key competitors?

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:

  • Chaim Hurvitz, Chairman of the Board (Age 56)
  • Allen Baharaff, Chief Executive Officer, Director (Age 49)
  • Antony Appleyard, Vice President – Drug Development (Age 39)
  • Maureen Graham, Vice President - Regulatory (Age 57)
  • George Tonelli, Vice President - Clinical Operations
  • Tal Yaron-Eldar, External Director Nominee (Age 52)
  • William S. Marth, Independent Director (Age 61)
  • Shmuel Nir, Independent Director (Age 52)

Who owns Galmed Pharmaceuticals stock?

Galmed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include 683 Capital Management LLC (5.10%), Meitav Dash Investments Ltd. (3.74%), Park West Asset Management LLC (2.30%), Sphera Funds Management LTD. (1.87%), J. Goldman & Co LP (0.49%) and Renaissance Technologies LLC (0.30%). View Institutional Ownership Trends for Galmed Pharmaceuticals.

Who bought Galmed Pharmaceuticals stock? Who is buying Galmed Pharmaceuticals stock?

Galmed Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Sphera Funds Management LTD., 683 Capital Management LLC, J. Goldman & Co LP, Renaissance Technologies LLC, Deutsche Bank AG and Park West Asset Management LLC. View Insider Buying and Selling for Galmed Pharmaceuticals.

How do I buy Galmed Pharmaceuticals stock?

Shares of Galmed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of Galmed Pharmaceuticals stock can currently be purchased for approximately $5.57.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $70.93 million and generates $470,000.00 in revenue each year. The biopharmaceutical company earns $-16,950,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Galmed Pharmaceuticals employs 16 workers across the globe.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.


MarketBeat Community Rating for Galmed Pharmaceuticals (GLMD)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galmed Pharmaceuticals (NASDAQ:GLMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.753.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.25$20.75$20.75$16.00
Price Target Upside: 135.20% upside105.85% upside181.17% upside124.40% upside

Galmed Pharmaceuticals (NASDAQ:GLMD) Consensus Price Target History

Price Target History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018Maxim GroupDowngradeBuy -> HoldHighView Rating Details
2/12/2018HC WainwrightBoost Price TargetBuy -> Buy$18.00 -> $24.00LowView Rating Details
11/15/2017Roth CapitalInitiated CoverageBuy -> Buy$32.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$19.00N/AView Rating Details
8/5/2016FBR & CoSet Price TargetBuy$20.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Galmed Pharmaceuticals (NASDAQ:GLMD) Earnings History and Estimates Chart

Earnings by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ GLMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018($0.22)N/AView Earnings Details
11/9/2017Q3 2017($0.27)($0.23)$0.26 million$0.27 millionViewN/AView Earnings Details
7/31/20176/30/2017($0.33)($0.22)$0.29 million$0.27 millionViewN/AView Earnings Details
5/15/20173/31/2017($0.39)($0.26)$0.29 million$0.27 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.30)($0.40)$0.22 million$0.27 millionViewN/AView Earnings Details
11/7/2016Q3($0.39)($0.34)$0.19 millionViewListenView Earnings Details
8/3/2016Q216($0.35)($0.39)ViewN/AView Earnings Details
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details
7/25/2014Q2 2014($0.15)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Galmed Pharmaceuticals (NASDAQ:GLMD) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.75 EPS

Dividends

Dividend History for Galmed Pharmaceuticals (NASDAQ:GLMD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galmed Pharmaceuticals (NASDAQ GLMD)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Galmed Pharmaceuticals (NASDAQ GLMD) News Headlines

Source:
DateHeadline
Galmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Hold" from AnalystsGalmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - February 22 at 3:06 PM
Galmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.23 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 20 at 1:22 AM
Galmed Pharmaceuticals Ltd (GLMD) Forecasted to Post FY2022 Earnings of $0.03 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Forecasted to Post FY2022 Earnings of $0.03 Per Share
www.americanbankingnews.com - February 19 at 9:18 AM
ValuEngine Lowers Galmed Pharmaceuticals (GLMD) to SellValuEngine Lowers Galmed Pharmaceuticals (GLMD) to Sell
www.americanbankingnews.com - February 14 at 11:42 PM
Galmed Pharmaceuticals (GLMD) Cut to "Hold" at Maxim GroupGalmed Pharmaceuticals (GLMD) Cut to "Hold" at Maxim Group
www.americanbankingnews.com - February 14 at 12:32 PM
Galmed Pharmas stock loses more than half its value after drug trial misses endpointGalmed Pharma's stock loses more than half its value after drug trial misses endpoint
finance.yahoo.com - February 14 at 9:51 AM
Galmed Announces ARRIVE Study DataGalmed Announces ARRIVE Study Data
finance.yahoo.com - February 14 at 9:51 AM
HC Wainwright Raises Galmed Pharmaceuticals (GLMD) Price Target to $24.00HC Wainwright Raises Galmed Pharmaceuticals (GLMD) Price Target to $24.00
www.americanbankingnews.com - February 12 at 11:46 AM
Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare ConferenceGalmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:11 AM
Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial BenefitsGalmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits
finance.yahoo.com - February 7 at 9:35 AM
Zacks: Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00Zacks: Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - February 5 at 6:58 AM
-$0.23 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter-$0.23 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter
www.americanbankingnews.com - February 3 at 3:14 AM
Galmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from AnalystsGalmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 29 at 3:30 AM
The Race To Find A Treatment For NASH - Nasdaq.com - NasdaqThe Race To Find A Treatment For NASH - Nasdaq.com - Nasdaq
www.nasdaq.com - January 16 at 9:58 AM
Galmed Pharmaceuticals (GLMD) Lowered to Hold at Zacks Investment ResearchGalmed Pharmaceuticals (GLMD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 11 at 11:54 PM
Zacks Investment Research Upgrades Galmed Pharmaceuticals (GLMD) to "Buy"Zacks Investment Research Upgrades Galmed Pharmaceuticals (GLMD) to "Buy"
www.americanbankingnews.com - January 11 at 12:10 AM
Galmed Pharmaceuticals Ltd (GLMD) Given Average Recommendation of "Buy" by BrokeragesGalmed Pharmaceuticals Ltd (GLMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 4 at 4:02 AM
Maxim Group Analysts Give Galmed Pharmaceuticals (GLMD) a $14.00 Price TargetMaxim Group Analysts Give Galmed Pharmaceuticals (GLMD) a $14.00 Price Target
www.americanbankingnews.com - January 3 at 8:00 PM
Galmed Pharma (GLMD) Reports Gross Proceeds of $11.6 Million Under ATM Programs During December 2017Galmed Pharma (GLMD) Reports Gross Proceeds of $11.6 Million Under ATM Programs During December 2017
www.streetinsider.com - January 3 at 9:17 AM
$280,000.00 in Sales Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter$280,000.00 in Sales Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter
www.americanbankingnews.com - January 2 at 4:12 PM
Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017
finance.yahoo.com - January 2 at 9:52 AM
Comparing Galmed Pharmaceuticals (GLMD) & Its RivalsComparing Galmed Pharmaceuticals (GLMD) & Its Rivals
www.americanbankingnews.com - January 1 at 1:22 PM
Head-To-Head Survey: Galmed Pharmaceuticals (GLMD) & Its RivalsHead-To-Head Survey: Galmed Pharmaceuticals (GLMD) & Its Rivals
www.americanbankingnews.com - January 1 at 1:22 PM
Zacks: Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) to Announce -$0.23 Earnings Per ShareZacks: Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) to Announce -$0.23 Earnings Per Share
www.americanbankingnews.com - December 31 at 9:28 AM
Galmed Pharmaceuticals (GLMD) vs. The Competition Head to Head ContrastGalmed Pharmaceuticals (GLMD) vs. The Competition Head to Head Contrast
www.americanbankingnews.com - December 30 at 5:14 PM
Galmed Pharmaceuticals (GLMD) versus Its Rivals Financial AnalysisGalmed Pharmaceuticals (GLMD) versus Its Rivals Financial Analysis
www.americanbankingnews.com - December 23 at 11:22 PM
Comparing Galmed Pharmaceuticals (GLMD) & The CompetitionComparing Galmed Pharmaceuticals (GLMD) & The Competition
www.americanbankingnews.com - December 23 at 1:12 PM
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD): Financial Strength AnalysisGalmed Pharmaceuticals Ltd (NASDAQ:GLMD): Financial Strength Analysis
finance.yahoo.com - December 19 at 9:59 AM
Analyzing Galmed Pharmaceuticals (GLMD) & Its RivalsAnalyzing Galmed Pharmaceuticals (GLMD) & Its Rivals
www.americanbankingnews.com - December 19 at 5:26 AM
Galmed Pharmaceuticals Ltd (GLMD) Expected to Announce Quarterly Sales of $280,000.00Galmed Pharmaceuticals Ltd (GLMD) Expected to Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - December 16 at 10:50 AM
Galmed Pharmaceuticals Ltd (GLMD) Given Average Rating of "Buy" by AnalystsGalmed Pharmaceuticals Ltd (GLMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 10 at 3:50 AM
Galmed Pharmaceuticals (GLMD) and Its Rivals Head to Head AnalysisGalmed Pharmaceuticals (GLMD) and Its Rivals Head to Head Analysis
www.americanbankingnews.com - December 9 at 9:10 PM
Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target by Maxim Group AnalystsGalmed Pharmaceuticals (GLMD) Given a $14.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - December 6 at 6:26 PM
Head to Head Analysis: Galmed Pharmaceuticals (GLMD) versus Its RivalsHead to Head Analysis: Galmed Pharmaceuticals (GLMD) versus Its Rivals
www.americanbankingnews.com - December 4 at 7:39 PM
Galmed Pharmaceuticals (GLMD) & AVEO Pharmaceuticals (AVEO) Head-To-Head ContrastGalmed Pharmaceuticals (GLMD) & AVEO Pharmaceuticals (AVEO) Head-To-Head Contrast
www.americanbankingnews.com - December 4 at 3:18 PM
Galmed Pharmaceuticals (GLMD) Downgraded by ValuEngine to "Sell"Galmed Pharmaceuticals (GLMD) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 12:44 PM
Galmed Pharmaceuticals Ltd. :GLMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Galmed Pharmaceuticals Ltd. :GLMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:04 AM
 Brokerages Expect Galmed Pharmaceuticals Ltd. (GLMD) Will Post Quarterly Sales of $280,000.00 Brokerages Expect Galmed Pharmaceuticals Ltd. (GLMD) Will Post Quarterly Sales of $280,000.00
www.americanbankingnews.com - November 28 at 9:52 AM
Galmed Pharmaceuticals to Present at HEP DART 2017 MeetingGalmed Pharmaceuticals to Present at HEP DART 2017 Meeting
finance.yahoo.com - November 27 at 5:40 PM
 Analysts Anticipate Galmed Pharmaceuticals Ltd. (GLMD) to Announce -$0.23 EPS Analysts Anticipate Galmed Pharmaceuticals Ltd. (GLMD) to Announce -$0.23 EPS
www.americanbankingnews.com - November 26 at 9:12 AM
Should You Buy Galmed Pharmaceuticals Ltd (GLMD) At $8.03?Should You Buy Galmed Pharmaceuticals Ltd (GLMD) At $8.03?
finance.yahoo.com - November 24 at 4:42 PM
Galmed Pharmaceuticals Ltd. (GLMD) Cut to "Hold" at Zacks Investment ResearchGalmed Pharmaceuticals Ltd. (GLMD) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 16 at 12:20 AM
Galmed Pharmaceuticals Ltd. (GLMD) Given Average Recommendation of "Buy" by AnalystsGalmed Pharmaceuticals Ltd. (GLMD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 15 at 12:06 PM
Galmed Pharmaceuticals Ltd. (GLMD) Research Coverage Started at Roth CapitalGalmed Pharmaceuticals Ltd. (GLMD) Research Coverage Started at Roth Capital
www.americanbankingnews.com - November 15 at 11:41 AM
Q4 2017 Earnings Forecast for Galmed Pharmaceuticals Ltd. Issued By Seaport Global Securities (GLMD)Q4 2017 Earnings Forecast for Galmed Pharmaceuticals Ltd. Issued By Seaport Global Securities (GLMD)
www.americanbankingnews.com - November 15 at 7:32 AM
Galmed Pharmaceuticals Ltd. (GLMD) Upgraded to "Buy" by Zacks Investment ResearchGalmed Pharmaceuticals Ltd. (GLMD) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 15 at 12:16 AM
Galmed Pharmaceuticals Ltd. to Host Earnings CallGalmed Pharmaceuticals Ltd. to Host Earnings Call
finance.yahoo.com - November 11 at 6:57 AM
Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateGalmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 11 at 6:57 AM
Galmed Pharmaceuticals reports 3Q lossGalmed Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 11 at 6:57 AM

SEC Filings

Galmed Pharmaceuticals (NASDAQ:GLMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galmed Pharmaceuticals (NASDAQ:GLMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galmed Pharmaceuticals (NASDAQ GLMD) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.